according to a recent study, published last month in the famous journal The Lancet, the injectable extended-release Naltrexone provides a good response in treatment of patients with opioid dependence ?
This research was conducted in thirteen clinical sites in Russia under the leadership of Dr. Evgeny Krupitsky, and consisted in a randomized double-blind, placebo-controlled trial, which lasted 24 weeks.
Naltrexone was injected to patients (a random sample of 250 subjects) after drug treatment of detoxification. Half of the sample were given the drug on a monthly basis, and the other half were injected with a placebo.
(Edited by María Moya Guirao, M.D.)